Gene Expression Profiling and Clinical Validation Reveal CEBPB for Early Diagnosis of Esophageal Squamous Cell Carcinoma
Cancer Reports · 2026-11 · 9 (11)
DOI: 10.1002/cnr2.70753 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Reports, online erschienen am 08.11.2026. Verfasst von Jihan Qi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China. Hauptthemen laut MEDLINE: Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Biomarkers, Tumor, CCAAT-Enhancer-Binding Protein-beta. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Esophageal squamous cell carcinoma (ESCC) accounts for over 90% of esophageal carcinoma cases in Asia, with early‐stage lack of reliable biomarkers and obvious symptoms leading to delayed diagnosis and poor prognosis.
Aims
This study aimed to screen and validate potential diagnostic biomarkers for early ESCC, and explore their regulatory roles in the tumor immune microenvironment. Methods and Results This study used weighted gene co‐expression network analysis to identify 1,204 genes strongly correlated with T1 stage tumors. Differential analysis showed 448 upregulated differentially expressed genes, mainly enriched in immune‐ and tumor‐related pathways. Through cross‐analysis, a protein‐protein interaction network was constructed and seven key genes were identified. External dataset validation and receiver operating characteristic curve analysis showed two key genes (CEBPB and CXCL8) had good diagnostic efficiency (AUC > 0.8). Although CXCL8 shows superior diagnostic performance in the GSE53625 transcriptomic dataset, we prioritize CEBPB based on consistent immunofluorescence validation in our tissue samples. Western blotting, immunohistochemistry and immunofluorescence preliminarily verified the expression feature of CEBPB in a small set of three paired clinical samples; larger independent cohorts are required before clinical application of CEBPB as a potential biomarker. Immune cell infiltration analysis revealed significant changes in macrophage populations in ESCC tissues. Five distinct cell types were identified in ESCC, with CEBPB expressed in all. Tissue stem cells and epithelial cells showed strong intercellular communication, while TGFB1‐(TGFBR1+TGFBR2) was widely expressed.
Conclusion
This study highlights CEBPB as a potential biomarker for ESCC, revealing its role in tumor progression and metastasis by modulating the immune microenvironment, providing insights for timely identification and precise management of ESCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
ORCID-Profile: Shizhu Jin
Zitieren
APA
Qi, J., Li, N., Chen, H., Geng, X., Cang, X., Gao, R., Jiang, X., Xu, L., Li, F., Wang, J., & Jin, S. (2026). Gene Expression Profiling and Clinical Validation Reveal CEBPB for Early Diagnosis of Esophageal Squamous Cell Carcinoma. Cancer Reports, 9(11). https://doi.org/10.1002/cnr2.70753
Vancouver
Qi J, Li N, Chen H, Geng X, Cang X, Gao R, et al. Gene Expression Profiling and Clinical Validation Reveal CEBPB for Early Diagnosis of Esophageal Squamous Cell Carcinoma. Cancer Reports. 2026;9(11). doi:10.1002/cnr2.70753
BibTeX
@article{Qi2026,
author = {Qi, Jihan and Li, Ning and Chen, Hongliang and Geng, Xinyu and Cang, Xueyu and Gao, Ranyan and Jiang, Xinyu and Xu, Lingyi and Li, Fengchun and Wang, Jiaxin and Jin, Shizhu},
title = {Gene Expression Profiling and Clinical Validation Reveal CEBPB for Early Diagnosis of Esophageal Squamous Cell Carcinoma},
journal = {Cancer Reports},
year = {2026},
volume = {9},
number = {11},
doi = {10.1002/cnr2.70753}
}
EUVIMED